Rallybio Stock Forum

$Rallybio (RLYB.US)$
Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting
Tuesday, 10th December at 8:00 am
Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the presentation of two posters highlighting promising preclinical data for pipeline candidates RLYB212 and RLYB332 at ...

$Rallybio (RLYB.US)$
Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025
Monday, 2nd December at 8:00 am
-- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study –
-- Manufacturing Process Enhancements Expected to Further Improve RLYB116 Tolerability --

$Rallybio (RLYB.US)$ Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
3 MINUTES AGO, 8:00 AM EST
VIA BUSINESSWIRE
— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial —

$Rallybio (RLYB.US)$
Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women
Rallybio announced the publication of a manuscript detailing target-mediated drug disposition (TMDD) modeling used to determine RLYB212 dosing for pregnant women.
The model incorporates pregnancy-related physiological changes and will be evaluated in their recently initiated Phase 2 clinical trial. RLYB212 is being developed ...

$Rallybio (RLYB.US)$
Rallybio Announces Initiation of Phase 2 Clinical Trial of RLYB212
— Screening is Now Underway to Identify Pregnant Women at Higher Risk for HPA-1a Alloimmunization and FNAIT —
Rallybio Corporation (NASDAQ:RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, today announced the initiation of its Phase 2 clinical trial investigating RLYB212 in pregnant women at higher risk ...

$Rallybio (RLYB.US)$ Reuters· just
Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of Rlyb212 in Pregnant Women at Higher Risk of Alloimmunization and Fnait

$Rallybio (RLYB.US)$
Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting
Rallybio (Nasdaq: RLYB) will present full data from an epidemiological analysis at the American Society of Human Genetics (ASHG) 2024 Annual Meetingin Denver, CO. The analysis quantifies the proportion of women across diverse populations at higher risk of a fetal and neonatal alloi...

$Rallybio (RLYB.US)$ Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis
2 MINUTES AGO, 8:00 AM EDT
VIA BUSINESSWIRE
– Study Demonstrates that RLYB212 Rapidly Clears HPA-1a Positive Platelets, an Essential Step in Preventing Alloimmunization and FNAIT –
– Rallybio On Track to Initiate RLYB212 Phase 2 Dose Confirmation Trial in Pregnant Women at Higher Risk for FNAIT in 4Q 2024 –

$Rallybio (RLYB.US)$ will it blast soon?

$Rallybio (RLYB.US)$ Johnson and Johnson partnership